Pharmaceuticals

Corifact Market Forecast 2026–2035: How to Leverage Market Growth

March 5, 2026March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the corifact market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Corifact Market covering 2026–2035?

The expansion observed historically stems from the identification of fibrinogen deficiency, advancements in trauma care, refined protocols for managing surgical bleeding, approvals of plasma-derived therapies, and their widespread adoption by hospitals.

The projected growth during the forecast period is driven by an increase in emergency surgical procedures, the specific needs of an aging population, the expansion of trauma centers, advancements in coagulation diagnostics, and a growing demand for rapid hemostatic agents.

Significant trends expected in the forecast period include a greater adoption of fibrinogen concentrates, an increased focus on achieving swift bleeding control, the broader expansion of trauma and surgical care services, the implementation of hospital-based hemostasis management, and a rising application in the treatment of liver diseases.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20024&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Corifact Market?

The corifact market is projected to expand due to the rising occurrence of bleeding disorders. These disorders are medical conditions that hinder the blood’s natural clotting ability, leading to prolonged or excessive blood loss. The increase in these conditions stems from enhanced diagnostic methods, greater public awareness, breakthroughs in genetic testing, along with shifts in lifestyle and the prevalence of underlying health issues. Corifact provides treatment for bleeding disorders resulting from factor XIII deficiency by supplying the missing clotting factor, which aids in forming stable blood clots and lessening profuse bleeding. As an illustration, in December 2023, data from the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO), a UK-based body, indicated the extent of bleeding disorders in 2023/24, documenting 6,835 individuals with haemophilia A, 1,378 with haemophilia B, in addition to 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Consequently, the growing incidence of bleeding disorders is a key factor propelling the corifact market’s expansion. The expanding demand for biological products is set to fuel the growth of the corifract market moving forward. Biological products are intricate pharmaceutical compounds derived from living organisms, utilized for diagnosing, preventing, treating, and curing various illnesses and health conditions. The escalating need for biological products can be attributed to growing environmental concerns, heightened consumer understanding, and the imperative for sustainable, effective alternatives to synthetic chemicals. Corifract plays a crucial role in supporting biological products by improving their stability, bioavailability, and effectiveness, thereby guaranteeing optimal performance and extended shelf life through cutting-edge formulation and delivery approaches. For example, in August 2025, according to the Assistant Secretary for Planning and Evaluation, a US-based government department, net revenue for biosimilars could range from a USD 33.5 million loss in smaller markets to USD 9.5 billion in larger ones; moreover, proposed regulatory modifications, including universal interchangeability, a global comparator, and the elimination of comparative efficacy studies, are estimated to reduce development expenses and boost lifetime revenues by USD 2 billion, USD 13.5 million, and USD 84 million, respectively. Thus, the increasing uptake of biological products is a significant driver for the corifract market.

What Leading Segments Are Studied In The Corifact Market?

The corifact market covered in this report is segmented –

1) By Product: Human-Derived Factor XIII, Recombinant Factor XII

2) By Therapeutic Applications: Routine Prophylactic Treatment, Peri-Operative Management

3) By Distribution Channels: Hospital Pharmacies, Specialty Pharmacies, Outpatient Clinics

Which Major Firms Are Strengthening Their Position In The Corifact Market?

Major companies operating in the corifact market are CSL Behring

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/corifact-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Corifact Market?

North America was the largest region in the corifact market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corifact market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Corifact Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20024&type=smp

Browse Through More Reports Similar to the Global Corifact Market 2026, By The Business Research Company

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Consumer Credit Market Report 2026

https://www.thebusinessresearchcompany.com/report/consumer-credit-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795